255 related articles for article (PubMed ID: 31710340)
1. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.
Tsai RM; Miller Z; Koestler M; Rojas JC; Ljubenkov PA; Rosen HJ; Rabinovici GD; Fagan AM; Cobigo Y; Brown JA; Jung JI; Hare E; Geldmacher DS; Natelson-Love M; McKinley EC; Luong PN; Chuu EL; Powers R; Mumford P; Wolf A; Wang P; Shamloo M; Miller BL; Roberson ED; Boxer AL
JAMA Neurol; 2020 Feb; 77(2):215-224. PubMed ID: 31710340
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.
VandeVrede L; La Joie R; Thijssen EH; Asken BM; Vento SA; Tsuei T; Baker SL; Cobigo Y; Fonseca C; Heuer HW; Kramer JH; Ljubenkov PA; Rabinovici GD; Rojas JC; Rosen HJ; Staffaroni AM; Boeve BF; Dickerson BC; Grossman M; Huey ED; Irwin DJ; Litvan I; Pantelyat AY; Tartaglia MC; Dage JL; Boxer AL
JAMA Neurol; 2023 May; 80(5):495-505. PubMed ID: 37010841
[TBL] [Abstract][Full Text] [Related]
3. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial.
Edwards AL; Collins JA; Junge C; Kordasiewicz H; Mignon L; Wu S; Li Y; Lin L; DuBois J; Hutchison RM; Ziogas N; Shulman M; Martarello L; Graham D; Lane R; Budd Haeberlein S; Beaver J
JAMA Neurol; 2023 Dec; 80(12):1344-1352. PubMed ID: 37902726
[TBL] [Abstract][Full Text] [Related]
4. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.
Wagshal D; Sankaranarayanan S; Guss V; Hall T; Berisha F; Lobach I; Karydas A; Voltarelli L; Scherling C; Heuer H; Tartaglia MC; Miller Z; Coppola G; Ahlijanian M; Soares H; Kramer JH; Rabinovici GD; Rosen HJ; Miller BL; Meredith J; Boxer AL
J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):244-50. PubMed ID: 24899730
[TBL] [Abstract][Full Text] [Related]
5. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
Boxer AL; Qureshi I; Ahlijanian M; Grundman M; Golbe LI; Litvan I; Honig LS; Tuite P; McFarland NR; O'Suilleabhain P; Xie T; Tirucherai GS; Bechtold C; Bordelon Y; Geldmacher DS; Grossman M; Isaacson S; Zesiewicz T; Olsson T; Muralidharan KK; Graham DL; O'Gorman J; Haeberlein SB; Dam T
Lancet Neurol; 2019 Jun; 18(6):549-558. PubMed ID: 31122495
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Ostrowitzki S; Bittner T; Sink KM; Mackey H; Rabe C; Honig LS; Cassetta E; Woodward M; Boada M; van Dyck CH; Grimmer T; Selkoe DJ; Schneider A; Blondeau K; Hu N; Quartino A; Clayton D; Dolton M; Dang Y; Ostaszewski B; Sanabria-Bohórquez SM; Rabbia M; Toth B; Eichenlaub U; Smith J; Honigberg LA; Doody RS
JAMA Neurol; 2022 Nov; 79(11):1113-1121. PubMed ID: 36121669
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration.
Illán-Gala I; Nigro S; VandeVrede L; Falgàs N; Heuer HW; Painous C; Compta Y; Martí MJ; Montal V; Pagonabarraga J; Kulisevsky J; Lleó A; Fortea J; Logroscino G; Quattrone A; Quattrone A; Perry DC; Gorno-Tempini ML; Rosen HJ; Grinberg LT; Spina S; La Joie R; Rabinovici GD; Miller BL; Rojas JC; Seeley WW; Boxer AL
JAMA Netw Open; 2022 Apr; 5(4):e229588. PubMed ID: 35486397
[TBL] [Abstract][Full Text] [Related]
8. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Teng E; Manser PT; Pickthorn K; Brunstein F; Blendstrup M; Sanabria Bohorquez S; Wildsmith KR; Toth B; Dolton M; Ramakrishnan V; Bobbala A; Sikkes SAM; Ward M; Fuji RN; Kerchner GA;
JAMA Neurol; 2022 Aug; 79(8):758-767. PubMed ID: 35696185
[TBL] [Abstract][Full Text] [Related]
11. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
[TBL] [Abstract][Full Text] [Related]
12. Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneneration Patterns in Corticobasal Syndrome.
Parmera JB; de Godoi Carneiro C; de Almeida IJ; de Oliveira MCB; Barbosa PM; Studart-Neto A; Ono CR; Nitrini R; Buchpiguel CA; Barbosa ER; Brucki SMD; Coutinho AM
Mov Disord Clin Pract; 2024 Mar; 11(3):238-247. PubMed ID: 38155526
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome.
Jabbari E; Holland N; Chelban V; Jones PS; Lamb R; Rawlinson C; Guo T; Costantini AA; Tan MMX; Heslegrave AJ; Roncaroli F; Klein JC; Ansorge O; Allinson KSJ; Jaunmuktane Z; Holton JL; Revesz T; Warner TT; Lees AJ; Zetterberg H; Russell LL; Bocchetta M; Rohrer JD; Williams NM; Grosset DG; Burn DJ; Pavese N; Gerhard A; Kobylecki C; Leigh PN; Church A; Hu MTM; Woodside J; Houlden H; Rowe JB; Morris HR
JAMA Neurol; 2020 Mar; 77(3):377-387. PubMed ID: 31860007
[TBL] [Abstract][Full Text] [Related]
14. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
Höglinger GU; Litvan I; Mendonca N; Wang D; Zheng H; Rendenbach-Mueller B; Lon HK; Jin Z; Fisseha N; Budur K; Gold M; Ryman D; Florian H;
Lancet Neurol; 2021 Mar; 20(3):182-192. PubMed ID: 33609476
[TBL] [Abstract][Full Text] [Related]
16. PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers.
Vasilevskaya A; Taghdiri F; Multani N; Anor C; Misquitta K; Houle S; Burke C; Tang-Wai D; Lang AE; Fox S; Slow E; Rusjan P; Tartaglia MC
Front Neurol; 2020; 11():574. PubMed ID: 32754109
[No Abstract] [Full Text] [Related]
17. Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.
Vossel K; Ranasinghe KG; Beagle AJ; La A; Ah Pook K; Castro M; Mizuiri D; Honma SM; Venkateswaran N; Koestler M; Zhang W; Mucke L; Howell MJ; Possin KL; Kramer JH; Boxer AL; Miller BL; Nagarajan SS; Kirsch HE
JAMA Neurol; 2021 Nov; 78(11):1345-1354. PubMed ID: 34570177
[TBL] [Abstract][Full Text] [Related]
18. Spatiotemporal characteristics of neurophysiological changes in patients with four-repeat tauopathies.
Samudra N; Lerner H; Yack L; Walsh CM; Kirsch HE; Kudo K; Yballa C; La Joie R; Gorno-Tempini ML; Spina S; Seeley WW; Neylan TC; Miller BL; Rabinovici GD; Boxer A; Grinberg LT; Rankin KP; Nagarajan SS; Ranasinghe KG
Ann Clin Transl Neurol; 2024 Feb; 11(2):525-535. PubMed ID: 38226843
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
